ORIGINAL RESEARCH article
Front. Oncol.
Sec. Breast Cancer
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1630702
Comprehensive Dosimetric Comparison of Halcyon 3.0 versus TrueBeam for Breast Cancer Volumetric Modulated Arc Therapy Plans
Provisionally accepted
- 1The Affiliated Huizhou Hospital, Guangzhou Medical University, Huizhou, China
- 2Guangdong Longken Central Hospital, Zhanjiang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Breast cancer is the foremost malignancy threatening female health.This study aimed to compare the dosimetric performance of Halcyon 3.0 and TrueBeam in Volumetric Modulated Arc Therapy (VMAT) planning for breast cancer.: Thirty post-operative breast cancer patients were included. VMAT plans for Halcyon 3.0 and TrueBeam were generated using 6MV FFF beams in Eclipse 16.1 with identical optimizing objectives. Organs At Risk (OARs) and target metrics were evaluated. Statistical analysis employed paired t-tests or Wilcoxon signed-rank tests (α=0.05).Results: Halcyon significantly reduced the mean dose of heart (Δ = -112.5 cGy, P < 0.001), left anterior descending artery mean dose (Δ = -151.3 cGy, P < 0.001), and spinal cord maximum dose (Δ = -88.2 cGy, P = 0.011). Low-dose exposure improved, with heart V5 (volume receiving ≥500 cGy) reduced from 22.0% to 12.6% (P < 0.001) and ipsilateral lung V5 reduced from 59.4% to 45.8% (P < 0.001) between Halcyon and TrueBeam. Halcyon lowered the absolute volume received 500 cGy by 487 cm³ (P < 0.001). Halcyon had the better target homogeneity (homogeneity index: Δ = -0.01, P < 0.001), while conformity remained comparable (P > 0.05). Despite having higher monitor units (Δ = 87.5, P < 0.001), Halcyon maintained delivery efficiency through faster leaf motion speed and gantry rotation velocity.Conclusions: Compared with TrueBeam, Halcyon achieved reduction in low-dose exposure while maintaining target coverage in breast cancer VMAT planning, thereby lowering radiation doses to OARs (e.g., heart and lung V5). This benefit is likely attributed to Halcyon's unique staggered dual-layer MLC design.
Keywords: Halcyon, Truebeam, breast cancer, volumetric modulated arc therapy, Radiotherapy plan
Received: 18 May 2025; Accepted: 31 Jul 2025.
Copyright: © 2025 Gu, Wang, Pan, Tang, Li, Wu, Yang and Xingru. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Sun Xingru, The Affiliated Huizhou Hospital, Guangzhou Medical University, Huizhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.